Abstract

ABSTRACT

Purpose: Age-related ocular disorders such as cataracts, glaucoma, and age-related macular degeneration (AMD) are major causes of visual impairment, especially in individuals over 40. These conditions are driven by multifactorial mechanisms, including oxidative stress and chronic inflammation. This study evaluates the efficacy and safety of EverBrite, a novel nutraceutical formulation containing lutein, zeaxanthin, DHA, EPA, vitamins C and E, zinc sulphate monohydrate, and Vaccinium myrtillus (bilberry) extract, designed to address multiple pathogenic pathways in ocular disease. Methods: A Phase I randomized controlled trial was conducted with 10 participants diagnosed with ocular conditions such as dry eye syndrome, conjunctivitis, photophobia, ocular allergies, and viral infections. Participants received the EverBrite formulation daily for 30 days. Clinical outcomes were assessed through symptom scoring and physician-observed ocular health improvements. Results: In a pilot clinical study, 70% of participants experienced clinically meaningful improvements, especially those with acute and chronic conjunctivitis. Over two years of real-world use following its release, the formulation has continued to deliver consistent benefits, including reduced eye inflammation, discharge, and discomfort. It has also been well tolerated, with no adverse effects reported. Conclusions: These preliminary results suggest that the EverBrite formulation may offer a safe and effective adjunctive strategy for managing age-related and inflammatory ocular disorders. These studies confirm the findings and explore the formulation’s impact on supporting eye health.